| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.9 |